News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novartis AG (NVS) Quarterly Profit Drops as Diovan, OTC Sales Slump



4/24/2012 7:12:05 AM

Novartis AG’s (NOVN) first-quarter profit dropped 8 percent on generic competition and manufacturing glitches at a consumer-health products factory in Nebraska. Net income excluding some costs fell to $3.09 billion, or $1.27 a share, from $3.4 billion, or $1.41 a share, a year earlier, the Basel, Switzerland-based company said in a statement today. Analysts predicted profit of $1.28 a share, the average of 10 estimates compiled by Bloomberg. Chief Executive Officer Joe Jimenez is facing the loss of billions in revenue as the company’s top-selling drug, Diovan, loses patent protection this year. The company, Europe’s biggest drugmaker, bought the Alcon eye-care business and has introduced new medicines such as Gilenya, the first pill for multiple sclerosis, to offset the losses.

Read at Bloomberg
Read at Washington Post
Read at Nasdaq
Read at Wall Street Journal


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES